Lindbrook Capital, LLC Affimed N.V. Transaction History

Lindbrook Capital, LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 24, 2023	BUY	$1.1 - $2.45 $191 - $426	174 New	174 $0
Q2 2022 Aug 01, 2022	SELL	$2.27 - $4.86 $401 - $860	-177 Closed	0 $0
Q1 2022 Apr 21, 2022	BUY	$3.69 - $5.65 $350 - $536	95 Added 115.85%	177 $1,000
Q4 2021 Jan 18, 2022	SELL	$5.37 - $7.07 $57,459 - $75,649	-10,700 Reduced 99.24%	82 $0
Q3 2021 Nov 05, 2021	SELL	$5.54 - $7.51 $5,085 - $6,894	-918 Reduced 7.85%	10,782 $67,000
Q2 2021 Jul 27, 2021	BUY	$7.78 - $11.4 $21,006 - $30,780	2,700 Added 30.0%	11,700 $99,000
Q1 2021 Apr 28, 2021	SELL	$5.12 - $8.48 $20,480 - $33,920	-4,000 Reduced 30.77%	9,000 $71,000
Q4 2020 Jan 27, 2021	BUY	$3.16 - $7.03 $25,280 - $56,240	8,000 Added 160.0%	13,000 $76,000
Q3 2020 Nov 03, 2020	SELL	$3.26 - $4.73 $27,012 - $39,192	-8,286 Reduced 62.37%	5,000 $17,000
Q2 2020 Jul 27, 2020	SELL	$1.58 - $4.63 $21,668 - $63,495	-13,714 Reduced 50.79%	13,286 $61,000
Q1 2020 Apr 22, 2020	BUY	$1.44 - $3.02 $31,680 - $66,440	22,000 Added 440.0%	27,000 $43,000
Q4 2019 Jan 27, 2020	SELL	$2.25 - $3.07 $11,250 - $15,350	-5,000 Reduced 50.0%	5,000 $14,000
Q2 2019 Jul 24, 2019	SELL	$2.6 - $4.21 $7,800 - $12,630	-3,000 Reduced 23.08%	10,000 $28,000
Q1 2019 Apr 23, 2019	BUY	$3.05 - $4.34 $1,525 - $2,170	500 Added 4.0%	13,000 $54,000
Q4 2018 Feb 07, 2019	BUY	$2.82 - $4.67 $35,250 - $58,375	12,500 New	12,500 $38,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $157M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Lindbrook Capital, LLC with notifications on news.